SwRI Receives $9.9 Million to Develop Nerve Agent Antidote

The use of nerve agents continues to be a significant threat to both military and civilian populations. This prototype medication could serve as a countermeasure against a nerve agent attack. SwRI will lead the development of the antidote under the $9.9 million, five-year program, and will collaborate with University of Pittsburgh on the synthesis and compound design, through the support of the Defense Threat Reduction Agency (DTRA).

“This antidote improves on the current standard of care, importantly, its ability to reverse the effects of the toxin in the central nervous system,” said SwRI’s Dr. Jonathan Bohmann, a principal scientist in SwRI’s Pharmaceutical and Bioengineering Department. “The antidote will eventually be administered through an autoinjector, which allows for rapid and effective treatment in the field. It would work much like an Epinephrine Auto-Injector or EpiPen^® administered during a severe allergy attack. The initial goal of the project is to support our warfighters; however, this treatment could also eventually be administered for civilian use.”

In the design of the new medication, SwRI will use a computer-based drug design software platform called Rhodium™. SwRI developed Rhodium™, a proprietary docking simulation software program tool, to enhance drug design and safety while reducing costs and speeding up development time. The Institute offers Rhodium as a service to clients.

SwRI is one of 193 industry, government and nonprofit organizations supporting the medical countermeasures sector in MCDC. This sector was founded to support U.S. Department of Defense needs in areas of infectious diseases, chemical threats and other medical countermeasures for military personnel.

SwRI’s Chemistry and Chemical Engineering Division is ISO 9001:2015 certified, meeting international quality standards for product development from initial design through production and service. SwRI scientists support drug development from discovery to clinical trials in FDA-inspected Current Good Manufacturing Practice facilities.

Rhodium supports drug development and screening for antibiotics as well as preventative treatments such as vaccines. The software also predicts adverse drug reactions and side effects.

For more information, visit https://www.swri.org/industries/pharmaceutical-development.

https://www.swri.org/press-release/rhodium-nerve-agent-antidote-dtra-mcdc

View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005106/en/